Wechselwirkungen · Loqtorzi
LOQTORZI 240 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 8
HOS-151537 · Präparat HOS-100567
No formal interaction studies have been performed. Since toripalimab is cleared from the circulation through catabolism, no metabolic drug-drug interactions are expected. Toripalimab is not a substrate for cytochrome P450 or active substance transporters. Toripalimab is not a cytokine and is unlikely to be a cytokine modulator. Additionally, pharmacokinetic (PK) interaction of toripalimab with small molecule active substances is not expected. There is no evidence of interaction mediated by non-specific clearance of lysosome degradation for antibodies.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-04T15:02:00Z · SHA-256 eac1acbe0bafe6f5114659e9ef7795b23454eef58d31a89daab4ae4684038d34 · Passage 3c07b7160fd3f187040b21cbe3568397a541d29643e990d961706f013475ff4f · Zeichen 0–557 im Abschnitt